Elmira Amooei

Dr. Elmira Amooei

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
EAElmira Amooei
Elmira Amooei
ABAmos Buh
Amos Buh
MKMartin Klamrowski
Martin Klamrowski
RSRisa Shorr
Risa Shorr
CMChristopher R McCudden
Christopher R McCudden
RKRan Klein
Ran Klein
Introduction Tacrolimus is an immunosuppressant commonly administered in transplant recipients. Given its narrow therapeutic range and susceptibility to various influencing variables, determining its optimal dosage is challenging. This systematic review seeks to identify effective analytical modelling techniques and methods for optimal tacrolimus dose prediction in solid transplant recipients. Methods and analysis This review will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. The study will review the literature published from database inception to 11 March 2024, that assesses predictive models of tacrolimus dosing through analytical modelling techniques. We will include both randomised and non-randomised, as well as cross-sectional, qualitative and before-and-after studies and will perform our searches in four main databases—Ovid/MEDLINE, PubMed/MEDLINE, Scopus, Embase and Web of Science, and search engines including Centers for Disease Control (CDC) and Google Scholar. Papers that are not published in English or French are excluded from this study. A narrative synthesis and meta-analysis will be done if the extracted information permits such analysis. Conference abstracts will be ignored unless they are recent (published within 2 years of the search date). Ethics and dissemination Ethics clearance is not required for this study as no primary data will be collected. The completed manuscript will be published, and the results of the study will be presented at conferences. Study registration International Prospective Register of Systematic Reviews (PROSPERO), CRD42024537212.

31 March 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EAElmira Amooei
Elmira Amooei
NBNandini Biyani
Nandini Biyani
ABAmos Buh
Amos Buh
MKMartin Klamrowski
Martin Klamrowski
NANawaf M Alyahya
Nawaf M Alyahya
RKRan Klein
Ran Klein
Background: Tacrolimus dose optimization remains challenging due to its narrow therapeutic range and multiple influencing variables. This systematic review aimed to identify effective analytical modeling techniques for optimal tacrolimus dose prediction in solid organ transplant recipients. Methods: Two independent researchers conducted a comprehensive review of studies examining analytical models that optimize tacrolimus dosing, searching Medline, Scopus, Embase, Web of Science, and PubMed. Results: In total, 115 studies met the inclusion criteria. Pharmacokinetic models (74 studies), particularly two-compartment with Bayesian forecasting, were most frequently used. Machine learning (ML) approaches, with increasing adoption, have demonstrated promising improved predictive accuracy. Key predictive variables included CYP3A5 genotype, hematocrit levels, post-operative days, and weight; however, the significance of genomic features seemed to diminish progressively as therapeutic drug monitoring calibrates dosing in the months following post-transplant. Only ten studies performed external validation, and none incorporated adherence data or predicted long-term graft outcomes. Conclusions: Clinical deployment of predictive models for tacrolimus dosing remains uncommon. In research, pharmacokinetic models remain prevalent, with ML approaches showing early incremental promise. Limited external validation raises generalizability concerns. Future research should prioritize outcome-based evaluation metrics rather than error metrics.